Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines
Copyright © 2022 by the American Academy of Pediatrics..
BACKGROUND: Temporal associations between Kawasaki disease (KD) and childhood vaccines have been reported. Limited data on KD following 13-valent pneumococcal conjugate (PCV13) and rotavirus vaccines are available.
METHODS: We conducted a self-controlled risk interval study using Vaccine Safety Datalink electronic health record data to investigate the risk of KD following PCV13 and rotavirus vaccines in children <2 years of age who were born from 2006 to 2017. All hospitalized KD cases identified by International Classification of Diseases diagnosis codes that fell within predefined risk (days 1-28 postvaccination) and control (days 29-56 for doses 1 and 2, and days 43-70 for doses 3 and 4) intervals were confirmed by manual chart review.
RESULTS: During the study period, 655 cases of KD were identified by International Classification of Diseases codes. Of these, 97 chart-confirmed cases were within risk or control intervals. In analyses, the age-adjusted relative risk for KD following any dose of PCV13 was 0.75 (95% confidence interval, 0.47-1.21). Similarly, the age-adjusted relative risk for KD following any dose of rotavirus vaccine was 0.66 (95% CI, 0.40-1.09). Overall, there was no evidence of an elevated risk of KD following PCV13 or rotavirus vaccines by dose. In addition, no statistically significant temporal clustering of KD cases was identified during days 1 to 70 postvaccination.
CONCLUSIONS: PCV13 and rotavirus vaccination were not associated with an increased risk of KD in children <2 years of age. Our findings provide additional evidence for the overall safety of PCV13 and rotavirus vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Pediatrics - 150(2022), 6 vom: 01. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kamidani, Satoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
13-valent pneumococcal vaccine |
|---|
| Anmerkungen: |
Date Completed 05.12.2022 Date Revised 02.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1542/peds.2022-058789 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348632495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348632495 | ||
| 003 | DE-627 | ||
| 005 | 20231226040724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1542/peds.2022-058789 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348632495 | ||
| 035 | |a (NLM)36349537 | ||
| 035 | |a (PII)e2022058789 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kamidani, Satoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.12.2022 | ||
| 500 | |a Date Revised 02.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 by the American Academy of Pediatrics. | ||
| 520 | |a BACKGROUND: Temporal associations between Kawasaki disease (KD) and childhood vaccines have been reported. Limited data on KD following 13-valent pneumococcal conjugate (PCV13) and rotavirus vaccines are available | ||
| 520 | |a METHODS: We conducted a self-controlled risk interval study using Vaccine Safety Datalink electronic health record data to investigate the risk of KD following PCV13 and rotavirus vaccines in children <2 years of age who were born from 2006 to 2017. All hospitalized KD cases identified by International Classification of Diseases diagnosis codes that fell within predefined risk (days 1-28 postvaccination) and control (days 29-56 for doses 1 and 2, and days 43-70 for doses 3 and 4) intervals were confirmed by manual chart review | ||
| 520 | |a RESULTS: During the study period, 655 cases of KD were identified by International Classification of Diseases codes. Of these, 97 chart-confirmed cases were within risk or control intervals. In analyses, the age-adjusted relative risk for KD following any dose of PCV13 was 0.75 (95% confidence interval, 0.47-1.21). Similarly, the age-adjusted relative risk for KD following any dose of rotavirus vaccine was 0.66 (95% CI, 0.40-1.09). Overall, there was no evidence of an elevated risk of KD following PCV13 or rotavirus vaccines by dose. In addition, no statistically significant temporal clustering of KD cases was identified during days 1 to 70 postvaccination | ||
| 520 | |a CONCLUSIONS: PCV13 and rotavirus vaccination were not associated with an increased risk of KD in children <2 years of age. Our findings provide additional evidence for the overall safety of PCV13 and rotavirus vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 650 | 7 | |a Rotavirus Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 650 | 7 | |a 13-valent pneumococcal vaccine |2 NLM | |
| 700 | 1 | |a Panagiotakopoulos, Lakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Licata, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Daley, Matthew F |e verfasserin |4 aut | |
| 700 | 1 | |a Yih, W Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbo, Ousseny |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, Hung Fu |e verfasserin |4 aut | |
| 700 | 1 | |a DeSilva, Malini B |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Jennifer C |e verfasserin |4 aut | |
| 700 | 1 | |a Groom, Holly C |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Joshua T B |e verfasserin |4 aut | |
| 700 | 1 | |a Hambidge, Simon J |e verfasserin |4 aut | |
| 700 | 1 | |a Donahue, James G |e verfasserin |4 aut | |
| 700 | 1 | |a Belay, Ermias D |e verfasserin |4 aut | |
| 700 | 1 | |a Weintraub, Eric S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatrics |d 1948 |g 150(2022), 6 vom: 01. Dez. |w (DE-627)NLM000021687 |x 1098-4275 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2022 |g number:6 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1542/peds.2022-058789 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2022 |e 6 |b 01 |c 12 | ||